METHOD FOR CONJUGATION OF HUMAN HEAVY CHAIN CONSTANT FRAGMENT AND PEPTOID ANALOGUE OF AUTOANTIGEN MOG35-55 FOR MULTIPLE SCLEROSIS THERAPY Russian patent published in 2020 - IPC C07K14/47 C07K1/14 C07K1/16 C07K1/36 A61K47/68 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, specifically to a method for conjugating a recombinant constant fragment of a human immunoglobulin heavy chain (Fc) and a peptoid analogue of autoantigen MOG35-55 (AMogP3). Chemical conjugation of Fc with a bifunctional cross-linker linker NHS-PEG2-maleimide is carried out at a ratio of reagents of 1:10 and an optimum length of the cross-linking reagent of 17.6 angstroms. Obtained fragment Fc-linker is purified from unreacted linker by means of desalting chromatographic column. Chemical conjugation of peptide AMogP3 carrying a free thiol group and a Fc-linker fragment are carried out at the ratio of reagents Fc-linker: peptoid = 1:2. Fc-linker: peptoid mixture is concentrated with cooling to 4 °C. Obtained bifunctional agent Fc-linker-peptoid module AMogP3 is purified from unreacted peptoid AMogP3 by gel filtration chromatography. Duration of one complete cycle of extraction and purification is 3 hours. Output of target product is 61.2 %. Invention improves efficiency of conjugation of peptoid analogue of autoantigen MOG35-55 with a constant domain of a heavy chain of human immunoglobulin.

EFFECT: prepared conjugate is suitable for multiple sclerosis therapy.

1 cl, 4 dwg, 1 tbl, 4 ex